Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sunshine Biopharma
(NQ:
SBFM
)
2.920
-0.310 (-9.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sunshine Biopharma
Sunshine Biopharma Announces Reverse Stock Split
August 06, 2024
Via
ACCESSWIRE
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
May 21, 2024
Via
ACCESSWIRE
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
April 19, 2024
Via
ACCESSWIRE
Sunshine Biopharma Announces Reverse Stock Split
April 12, 2024
Via
ACCESSWIRE
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
April 01, 2024
Via
ACCESSWIRE
Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief Financial Officer Purchases Shares
December 27, 2022
To learn more about Sunshine Biopharma, download the latest research report here
Via
TheNewswire.com
Exposures
COVID-19
NASDAQ: SBFM 👥 Enters Into A Collaboration Agreement For Its K1.1 Anticancer mRNA Project! 🔬
November 23, 2022
Christine Petraglia - TraDigital IR
Via
TheNewswire.com
BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes on $10M Public Offering
February 15, 2024
Via
Investor Brand Network
Exposures
COVID-19
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
February 13, 2024
Via
ACCESSWIRE
Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition
November 13, 2023
Via
ACCESSWIRE
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)
May 16, 2023
Via
ACCESSWIRE
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
February 28, 2023
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT
February 28, 2023
Montreal – February 28, 2023 – Sunshine Biopharma Inc. (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and...
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed
December 08, 2022
Read the latest report on Sunshine Biopharma here.
Via
TheNewswire.com
Exposures
COVID-19
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
November 17, 2022
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body....
Via
FinancialNewsMedia
Exposures
COVID-19
Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Aegis Capital Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ: SBFM)
March 15, 2022
NEW YORK, NY / ACCESSWIRE / March 15, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ:SBFM) About Sunshine...
From
Aegis Capital Corp.
Via
AccessWire
Exposures
COVID-19
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW)
February 17, 2022
NEW YORK, NY / ACCESSWIRE / February 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ:SBFM; SBFMW)...
From
Aegis Capital Corp.
Via
AccessWire
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.